LOGIN  |  REGISTER
C4 Therapeutics
C4 Therapeutics

DocGo Announces Upcoming Participation at Stifel Cross Sector Insight Conference

May 21, 2024 | Last Trade: US$2.12 0.07 -3.20

NEW YORK / May 21, 2024 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo”), a leading provider of technology-enabled mobile health services, today announced that Lee Bienstock, Chief Executive Officer, will present at the Stifel Cross Sector Insight Conference on Wednesday, June 5 at 1:15 PM Eastern Time. A webcast of the event will be available on the investor relations section of DocGo’s website at https://ir.docgo.com/.

About DocGo

DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page